In agreement with these results, Giulino-Roth and collaborators found that HSP90α inhibition targets multiple components of the PAM signalling in Burkitt’s lymphoma (BL), highlighting its importance in cancer therapy102. This evidence concerns the gene HSP90AA1 and cancer.